Hepatitis C Virus Direct Acting Antivirals and Disruptive Innovation

S. Mantravadi; D. Snider

doi:10.33423/jsis.v12i2.802

Hepatitis C Virus Direct Acting Antivirals and Disruptive Innovation

Authors

S. Mantravadi University of West Florida
D. Snider University of West Florida

DOI:

https://doi.org/10.33423/jsis.v12i2.802

Keywords:

Sustainability, Innovation, Business, Pharmaceutical, Hepatitis, Market

Abstract

In 2011, a new wave of direct acting antiviral treatments to combat the hepatitis C virus entered the market. In this paper we discuss how the entrance of these pharmaceutical products fit the definition of a disruptive innovation along with how they affected patients, providers and insurers.

Downloads

Published

2017-12-01

How to Cite

Mantravadi, S., & Snider, D. (2017). Hepatitis C Virus Direct Acting Antivirals and Disruptive Innovation. Journal of Strategic Innovation and Sustainability, 12(2). https://doi.org/10.33423/jsis.v12i2.802